4 results
To improve response rate of primary treatment of extensive chronic GvHD with the addition of MPA to the reference treatment CsA+PDN (comparator)Primary ObjectiveTo improve remission rates with cyclosporine A+ prednisone + Myfortic® (CsA+PDN+MPA)…
The primary aim is to study the effect of treatment of severe AD patients with Myfortic on DNA-repair after irradiation with UVB.A secondary aim is to study the effect of treatment of severe AD patients on atopic status, measured as total IgE and…
To evaluate safety of 3-months versus standard 12-months of DAPT
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.